BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23539885)

  • 1. Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.
    Miller CE; Zbella E; Webster BW; Doody KJ; Bush MR; Collins MG
    J Reprod Med; 2013; 58(3-4):153-60. PubMed ID: 23539885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer.
    Devroey P; Pellicer A; Nyboe Andersen A; Arce JC;
    Fertil Steril; 2012 Mar; 97(3):561-71. PubMed ID: 22244781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation.
    Doody KJ; Schnell VL; Foulk RA; Miller CE; Kolb BA; Blake EJ; Yankov VI
    Fertil Steril; 2009 Apr; 91(4):1012-7. PubMed ID: 18371963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support.
    Beltsos AN; Sanchez MD; Doody KJ; Bush MR; Domar AD; Collins MG
    Reprod Health; 2014 Nov; 11():78. PubMed ID: 25385669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.
    Bosch E; Vidal C; Labarta E; Simon C; Remohi J; Pellicer A
    Hum Reprod; 2008 Oct; 23(10):2346-51. PubMed ID: 18583332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM; Kolibianakis EM; Camus M; Tournaye H; Donoso P; Papanikolaou E; Devroey P
    Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
    Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
    JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative randomized controlled study between human follicle- stimulating hormone (FSH-HP) and human menopausal gonadotropins (hMG) in in vitro fertilization].
    Mayenga JM; Belaisch-Allart J; Chouraqui A; Tesquier L; Serkine AM; Cohen J; Plachot M; Mandelbaum J
    Contracept Fertil Sex; 1997 May; 25(5):371-4. PubMed ID: 9273107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer.
    Mitwally MF; Diamond MP; Abuzeid M
    Fertil Steril; 2010 Feb; 93(2):554-69. PubMed ID: 19362305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.
    Andersen AN; Devroey P; Arce JC
    Hum Reprod; 2006 Dec; 21(12):3217-27. PubMed ID: 16873892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol.
    Shavit T; Shalom-Paz E; Samara N; Aslih N; Michaeli M; Ellenbogen A
    Gynecol Endocrinol; 2016 Aug; 32(8):629-633. PubMed ID: 26939574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
    Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
    Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
    Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
    Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
    Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.